[1] 中华医学会糖尿病学分会 . 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4):315-409.
[2] Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016, 375(4): 311-322.
[3] 司美格鲁肽治疗2型糖尿病合并动脉粥样硬化性心血管疾病1例. 中华糖尿病杂志，2022, 14(增刊): 134-137.
[4] Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP‑1 receptor agonists in patients with type 2 diabetes: a systematic review and meta‑analysis of cardiovascular outcome trials [J]. Lancet Diabetes Endocrinol, 2019, 7(10): 776‑785.
